Latest Conference Articles

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.

Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

Steven E. Finkelstein, MD, DABR, FACRO, discusses the importance of disseminating treatment advancements and ongoing research in radiation oncology.

Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.

Treatment with XPO1 inhibitors could be effective and warrants further investigation in low-grade serous and clear cell ovarian cancer.

ctDNA may aid clinicians in determining whether to proceed with or discontinue PARP inhibitor maintenance therapy for patients with recurrent epithelial ovarian cancer.

NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Ixabepilone plus bevacizumab produced a survival advantage and high response rates vs ixabepilone alone in platinum-resistant ovarian cancer.

A phase 1b trial is investigating the novel GCN2 kinase activator NXP800 in patients with platinum-resistant, ARID1A-mutated ovarian cancer.

CRX100 plus a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in patients with recurrent, platinum-resistant ovarian cancer.

Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.

Lenvatinib plus pembrolizumab did not best chemotherapy in pMMR endometrial cancer, but did offer a survival benefit in some subgroups of patients.

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.